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Abstract
Background: Mutations in the BRCA1, BRCA2 and PALB2 genes are well-established risk factors for the
development of breast and/or ovarian cancer. The frequency and spectrum of mutations in these genes has not
yet been examined in the population of Southern Poland.
Methods: We examined the entire coding sequences of the BRCA1 and BRCA2 genes and genotyped a recurrent
mutation of the PALB2 gene (c.509_510delGA) in 121 women with familial and/or early-onset breast or ovarian
cancer from Southern Poland.
Results: A BRCA1 mutation was identified in 11 of 121 patients (9.1 %) and a BRCA2 mutation was identified in
10 of 121 patients (8.3 %). Two founder mutations of BRCA1 accounted for 91 % of all BRCA1 mutation carriers
(c.5266dupC was identified in six patients and c.181 T > G was identified in four patients). Three of the seven
different BRCA2 mutations were detected in two patients each (c.9371A > T, c.9403delC and c.1310_1313delAAGA).
Three mutations have not been previously reported in the Polish population (BRCA1 c.3531delT, BRCA2
c.1310_1313delAAGA and BRCA2 c.9027delT). The recurrent PALB2 mutation c.509_510delGA was identified in
two patients (1.7 %).
Conclusions: The standard panel of BRCA1 founder mutations is sufficiently sensitive for the identification of BRCA1
mutation carriers in Southern Poland. The BRCA2 mutations c.9371A > T and c.9403delC as well as the PALB2
mutation c.509_510delGA should be included in the testing panel for this population.
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Background
Inherited mutations in the DNA repair genes BRCA1
and BRCA2, discovered and cloned almost 20 years ago,
are associated with significantly increased risks of both
breast and ovarian cancer [1–6]. The BRCA1/2 proteins
participate in molecular repair pathways in response to
DNA damage; BRCA1 is involved in the recognition of
DNA damage and the regulation of cell cycle arrest and
BRCA2 regulates the key homologous recombination
enzyme Rad51 [7–14]. In addition to BRCA1/2, several
other genes have been identified which predispose women
to breast and/or ovarian cancer. Genes with high pene-
trance (i.e. relative risk of four or more) include TP53,
PTEN and PALB2 [15–17]. Genes with moderate or low
penetrance (i.e. relative risk of 1.5 to 3) include ATM,
CHEK2, NBS1, and BRIP1 [18–21].
In Poland, a relatively small number of founder muta-
tions in genes of high or moderate penetrance account
for the majority of breast and/or ovarian cancer families.
Among them are six mutations of BRCA1 (c.68_69delAG,
c.181 T >G, c.3700_3704del, c.4035delA, c.5266dup and
c.5251C > T) of BRCA1 mutations, a single mutation
of NBS1 (c.657_661delACAAA) and two recently de-
scribed mutations of PALB2 (c.509_510delGA and c.172_
175delTTGT) [21–23]. Some recurrent mutations of
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BRCA2 have been reported (c.658_659delGT, c.3847_
3848delGT, c.5239_5240insT, c.5946delT and c.7913_
7917del), but the frequency of these mutations in Polish
families is relatively low [19, 23, 24]. Kluska et al. recently
proposed that the testing panel of Polish founder
mutations be expanded to include two new mutations,
c.1687C > T in BRCA1 and c.9371A > T in BRCA2 with
the status pathogenic and likely pathogenic respectively,
which showed strong founder effects in Polish patients
with familial or early-onset breast and/or ovarian cancer
[25]. Although the set of the most frequent deleterious
mutations described above is generally accepted, there
have been significant discrepancies in the frequency of re-
current mutations reported in different regions of Poland.
Based on the data published previously by different Polish
groups, we have decided that the set of five BRCA1
mutations (c.68_69delAG, c.181 T >G, c.3700_3704del,
c.4035delA, c.5266dup), which is covering approximately
90 % of all detected in BRCA1 mutations associated
with familial breast and ovarian cancer syndrome
might be treated as a “standard panel” for Polish popula-
tion [21, 23, 26–28].
The aim of our study was to identify the optimal panel
of founder mutations for the genetic screening of pa-
tients at high risk for hereditary breast and/or ovarian
cancer in Southern Poland. We compared the frequency
and spectrum of BRCA1 and BRCA2 mutations contribut-
ing to breast and ovarian cancer families in Malopolska
with those that have been previously reported in
Polish families. We also examined the frequency of
the recurrent PALB2 deletion c.509_510delGA in this
population.
Methods
Patient group
We studied 121 women diagnosed with breast or ovarian
cancer from families fulfilling one of the following cri-
teria: 1) three or more breast and/or ovarian cancer
cases in first or second-degree relatives, 2) synchronous
or metachronous breast and/or ovarian cancer in the
same patient, 3) two breast cancer cases in first-degree
relatives (at least one diagnosed before age 50) or 4)
breast cancer diagnosed before age 40. All patients in
the study were recruited between 2012 and 2014 from
three oncology centers in Małopolska: (i) Oncology
Cancer Center Institute Marie Skłodowska-Curie, De-
partment in Kraków, (ii) Outpatient Clinic of Early
Diagnosis and Treatment of Breast Disease, Collegium
Medicum Jagiellonian University, Kraków and (iii)
Outpatient Clinic of Oncological Surgery, St. Raphael
Hospital, Kraków. Written consent for genetic testing
was obtained for all patients. This study was approved
by the Ethics Committee (decision No. 71/KBL/OIL/
2012).
DNA isolation
Genomic DNA was isolated from 200 ul of peripheral
blood on Extractme silica columns (EURx) according to
the manufacturer’s protocol. The quality and concentra-
tion of extracted DNA was assessed using NanoDrop
2000 (ThermoScientific).
HRM analysis
The BRCA1 coding sequence with flanking intronic se-
quences were analyzed for all patients using the High
Resolution Melting (HRM) method. The HRM method
is a commonly used for the detection of single nucleo-
tide substitutions and small oligonucleotide insertion or
deletion variants and has been shown to be suitable for
the detection of BRCA1 mutations [29–31]. Primers
were designed to amplify a fragment no longer than
300 bp to enable mutation detection. Coding sequences
longer than 300 bp were covered with amplicons with
overlapping flanking sequences. Optimal annealing
temperature was established employing gradient PCR.
Agarose gels were run for each primer set to ensure that
the correct size product was produced and that there
was no formation of non-specific products. The thermal
cycling profile consisted of a three minute initial activa-
tion at 95 °C, 45 3-step cycles (5 s denaturation at 95 °C,
annealing for 10 s, 10 s extension at 72 °C) and a final
hold at 72 °C for 10 s. For the HRM analysis, fluores-
cence data acquisition was set from 77 °C to 89 °C,
increasing the temperature by 0.1 °C each step. 20 ng
of genomic DNA was added to the PCR mix contain-
ing primers pair and SensiFAST HRM kit (Bioline).
42 amplicons were used to analyze the BRCA1 se-
quence. A known homozygous wild type control and
a no-template control were also included in the analyzed
sample sets. The analysis was performed on Rotor-Gene
Q 5plex HRM Platform (Qiagen). Samples with an
aberrant melting profile were sequenced using Sanger
sequencing.
DNA sequencing
The BRCA2 coding sequence with flanking intronic se-
quence and the PALB2 mutation c.509_510delGA were
analyzed for all patients using Sanger sequencing.
Amplicons were sequenced using BigDye Terminator
v3.1 Cycle Sequencing Kit and 3130xl Genetic Analyzer
(Applied Biosystems). Sequencing data were examined
using Sequencing Analysis software 5.2 and compared to
reference sequences. Nucleotide reference sequences
were as follows: BRCA1 (NM_007294.3, NG_005905.2),
BRCA2 (NM_000059.3, NG_012772.3), PALB2 (NM_
024675.3, NG_007406.1). Each detected mutation was
confirmed by independent analysis starting from DNA
extraction.
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Results
We screened 121 women with familial and/or early-
onset breast or ovarian cancer for mutations in BRCA1,
BRCA2 and PALB2. The mean age of cancer diagnosis
for all patients was 48.5 years (range 27–85 years). There
were 115 women with breast cancer (mean age of diag-
nosis: 48.6 years) and six women with ovarian cancer
(mean age of diagnosis: 46.7 years).
A mutation in one of the three genes was detected in
23 of 121 patients (19.0 %). A BRCA1 mutation was
identified in 11 patients (9.1 %) and a BRCA2 mutation
was identified in ten patients (8.3 %). The PALB2 mutation
c.509_510delGA was identified in two patients (1.7 %).
Molecular and clinical characteristics of the mutation-
positive patients are presented in Table 1.
Two common founder mutations of BRCA1 accounted
for 91 % of all BRCA1 mutation carriers. The BRCA1
founder mutation c.5266dupC was identified in six
patients (54.5 % of all BRCA1 carriers), and the BRCA1
founder mutation c.181 T > G was identified in four pa-
tients (36.4 % of all BRCA1 carriers). One patient was
found to carry a rare BRCA1 mutation c.3531delT
(9.1 % of all BRCA1 carriers). This variant has not been
previously reported in the Polish population (Table 2).
In the group of 10 patients harboring BRCA2 muta-
tions, seven different single mutations have been detected.
Three mutations (c.1310_1313delAAGA, c.9371A > T and
c.9403delC) were identified in two patients each and four
mutations (c.6267_6269delinsC, c.9027delT, c.7913_7917
delTTCCT and c.10095delCinsGAATTATATCT) were
identified in one patient each. Two of the BRCA2
mutations (c.1310_1313delAAGA and c.9027delT) have
not been previously reported in the Polish population
(Table 3).
In addition to the pathogenic mutations described
above, several synonymous and non-synonymous variants
Table 1 Molecular and clinical characteristics of mutation-positive patients
Patient Type of cancer Mutation Age of onset Number of ovarian
cancers in family
Number of breast
cancers in family
BRCA1
1 Breast cancer c.181 T > G, p.C61G
“standard panel” mutation
43 2 0
2 Bilateral breast 35/42 0 6
3 Breast cancer 42 2 0
4 Breast cancer 25 2 2
5 Ovarian cancer c.3531delT, p.F1177Lfs*33 39 1 0
6 Breast cancer c.5266dupC, p.Q1756Pfs*74
“standard panel” mutation
59 3 0
7 Ovarian cancer 59 4 0
8 Breast cancer 44 0 1
9 Breast cancer 55 1 0
10 Breast cancer 44 1 1
11 Bilateral breast 25 1 0
BRCA2
1 Breast cancer c.1310_1313delAAGA,
p.Lys437Ilefs*22
37 0 1
2 Breast cancer 38 0 4
3 Breast cancer c.6267_6269delinsC,
p.E2089_H2090delinsDfs*2
41 0 3
4 Bilateral breast c.7913_ 7917delTTCCT, p.F2638* 40 0 1
5 Breast cancer c.9027delT, p.Y3009Yfs*19 52 1 1
6 Breast cancer c.9371 A > T, p.N3124I 67 1 1
7 Bilateral breast - 2 1
8 Bilateral breast c.9403delC, p.L3135Ffs*28 36 0 1
9 Breast cancer 37 2 1
10 Breast cancer c.10095delCinsGAATTATATCT, p.V3365Vfs*5
(non-pathogenic)
61 0 1
PALB2
1 Breast cancer c.509_510delGA <50 0 1
2 Breast cancer 48 0 2
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were detected in the analyzed genes, including ten in
BRCA1 (c.734A > T, c.1067A >G, c.2077 G > A, c.20
82C > T, c.2311 T > C, c.3113A >G, c.3548A >G, c.403
9A >G, c.4308 T > C, c.4837A >G), nine in BRCA2 (c.33
96 A >G, c.3516 G > A, c.3807 T > C, c.5199 C > T, c.57
44C > T, c.7242A >G, c.8182G > A, c.8850G > T, c.1020
2C > T) and one in PALB2 (c.1010 T > C).
Two of the 11 BRCA1 mutations were identified in
women with high-grade serous ovarian cancer and nine
were identified in women with breast cancer. Of the
six BRCA1 mutation-associated breast cancers with
information on histopathology, hormone receptor
status and HER2 status, four were triple-negative (ER/
PR/HER2-negative) invasive ductal carcinomas and two
were atypical medullary breast cancers (ER/PR-positive,
HER2-negative). All nine BRCA2 mutations were
identified in women with breast cancer. Of the eight
BRCA2 mutation-associated breast cancers with infor-
mation on histopathology, hormone receptor status and
HER2 status, five were ER/PR-positive, HER2-negative
invasive ductal carcinomas and three were ER/PR-
positive, HER2-positive invasive ductal carcinomas. Both
Table 2 Frequency of rare (non-founder) BRCA1 mutations reported in the Polish population
BRCA1 mutation Perkowska
(2003)
[39]
Górski
(2004)
[32]
Brożek
(2008)
[35]
Ratajska
(2008)
[26]
Rzepecka
(2012)
[54]
Gaj
(2012)
[55]
Cybulski
(2014)
[24]
Ratajska
(2015)
[27]
Szwiec
(2015)
[49]
Kluska
(2015)
[2015]
Current
study
N = 60 N = 200 n = 151 N = 64 n = 257 n = 906 n = 144 n = 134 n = 1164 n = 512 n =121
c.342_343delTC - - - - - - - - - 1 -
c.405_408delAAGA - - - - - - - - - 1 -
c.406delA - - - - - - - - - 1 -
c.594-2A > C - - - - - - - 1 - - -
c.676delT - 2 - - - - - - - - -
c.1612C > T - - - - - - - - - 1 -
c.1687C > T - - 2 - - - 1 - - 8 -
c.1695_1696insG - - - - - - - - - 1 -
c.1793 T > A - - - - - - - 1 - - -
c.2563C > T 1 - - - - - - - - - -
c.2866_2870delTCTCA - 1 - - - - - - - - -
c.2872_2876delTTCAG - - - 1 - - - - - - -
c.3531delT - - - - - - - - - - 1
c.3748G > T - - - - 1 - - - - - -
c.3756_3759delGTCT - - - - 3 4 - - - - -
c.3779delT - - - - - 2 - - - - -
c.3817C > T - - - 1 - - - - - - -
c.4041_4042delAG - - - - - 1 1 - - - -
c.4357 + 2 T > G - - - - - - - 1 - - -
c.4484 + 1G > A 1 - 1 - - - - - - - -
c.4516delG - - - - - - - - - 4 -
c.4597_4598delGA - - - - - - - - - 1 -
c.4689C > G - - - - - - - - - 1 -
c.5030_5033delCTAA - 1 - - - - - - - - -
c.5095C > T - - - - - - - - - 2 -
c.5137delG - - - - - - - - - 1 -
c.5177_5180delGAAA - - - - - - 1 - - - -
c.5232del7ins12 - - - - - - - - - 1 -
c.5251C > T - 3 - - - 8 1 - 3 - -
c.5289insG - - - - - - - - - 1 -
c.5346G > A 1 - - - - - 1 - - 2 -
n – represents number of patients included to the study; N – represents number of families included to the study
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Table 3 Overview of mutations found in the BRCA2 gene in the Polish population
Looij
(2000)
[52]
Grzybowska
(2000)
[34]
Kwiatkowska
(2001) [42]
Perkowska
(2003)
[39]
Górski
(2004)
[32]
Brożek
(2008)
[35]
Ratajska
(2008)
[26]
Balabas
(2010)
[36]
Gaj
(2012)
[55]
Cybulski
(2014)
[24]
Ratajska
(2015)
[27]
Szwiec
(2015)
[22]
Kluska
(2015)
[25]
Current
study
N = 25 N = 47 n = 37 N = 60 N = 200 n = 151 N = 64 n = 105 n = 906 n = 144 n = 134 n = 1164 n = 512 n = 121
c.2 T > C - - - - - - - - - 1 - - - -
c.22_23delAG - - - - - - - - - 1 - - - -
c.262_263delCT - - - - 1 - - - - - - - - -
c.274C > T - - - - - - - - - - - - 1 -
c.658_659delGT - - - - - - - - - - - 1 - -
c.700delT - - - - - - - - - - - - 1 -
c.1180G > T - - - - - - - 1 1 - - - - -
c.1310_1313delAAGA - - - - - - - - - - - - - 2
c.1318_1321delCTTA - - - - - - - - - - - - 1 -
c.1813_1814insA - - 1 - - - - - - - - - - -
c.2806_2809delAAAC - - - - - - - - - 1 - - - -
c.2808_2811delACAA - - - - - - - - - - 1 - 1 -
c.3199delA - - - - 1 - - - - - - - - -
c.3847_3848delGT 1 - - - - - - - - - - 1 - -
c.3860delA - - - 1 - - - - - - - - - -
c.3975_3981dupTGCT - - - - - 1 - - - 1 1 - - -
c.4223delA - - - - - 1 - - - - - - - -
c.5042_5043delTG - - - - - - - - - - 1 - - -
c.5239_5240insT - - - - 1 - - 1 4 - - 1 - -
c.5722_5723delCT - - - - - - - - - 1 - - - -
c.5946delT - - - - - - - 1 4 - - 1 - -
c.5964_5965delAT - - - - - - - 1 - - - - - -
c.6010_6030delinsTT - - - - - - 1 - - - - - - -
c.6267_6269delGCAinsC - - 1 - - - - - - - - - - 1
c.6275_6276delTT - - - - - - - - - 1 - - - -
c.6393_6396delATTA - - - - - 1 - - - - - - - -
c.6402_6406delTAACT - - - - - - - - - 1 - - - -
c.6447_6448delTA - - - - - - - 1
c.6658_6662delGAAAA - 1 - - - - - - - - - - - -
c.7007G > A - - - - 1 - - - - - - - - -
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Table 3 Overview of mutations found in the BRCA2 gene in the Polish population (Continued)
c.7180A > T - - - - - - - - - - 1 - - -
c.7251_7252delCA - - - - - - - - - 1 - - 1 -
c.7080_7099dup 1 - - - - - - - - - - - - -
c.7913_7917delTTCCT - - 1 - 1 - - 3 2 - - 1 - 1
c.8648delC - - - - - - 1 - - 1 - - - -
c.8842delA 1 - - - 1 - - - - - - - 1 -
c.8924delT - - - - - - - 1 1 - - - - -
c.8946delA - - - - - - - - - - - - 1 -
c.9027delT - - - - - - - - - - - - - 1
c.9097_9098insA - - - - - - - 1 - 1 - - - -
c.9118-2A > G - - - - - - - 1 - - - - 3 -
c.9138C > T - - - - - - - - - - - - 1 -
c.9253_9254insA - - - - - - - - - 1 - - - -
c.9371A > T - 1 1 - - - - 3 - - - - 6 2
c.9376delC - - - - - - - - - - - - 1 -
c.9403delC - 3 - - 1 - - 1 - 1 - - - 2
c.10095delCinsGAATTATATCT - - - - - - 2 1 - - - - - 1
n – represents number of patients included to the study; N – represents number of families included to the study
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PALB2 mutation-associated breast cancers were ER/PR-
positive invasive ductal carcinomas with coexisting ductal
carcinoma in situ.
Discussion
We identified a BRCA1/2 mutation in 21 (17.4 %) of 121
patients with familial and/or early-onset breast or ovar-
ian cancer from Southern Poland. A BRCA1 mutation
was identified in 11 patients (9.1 %) and a BRCA2 muta-
tion was identified in ten patients (8.3 %). The preva-
lence of BRCA1/2 mutations is relatively low compared
to previous studies of Polish breast and/or ovarian can-
cer families, in large part due to the low frequency of
BRCA1 mutations. In a study of 200 Polish families with
three or more breast or ovarian cancers a BRCA1/2 mu-
tation was identified in 64 %; the prevalence of BRCA1
mutations was 60 % and the prevalence of BRCA2 mu-
tations was 4 % [32]. In a study of Northern Polish
families with similar characteristics as the families in our
study, a BRCA1/2 mutation was identified in 67 %; the
prevalence of BRCA1 mutations was 61 % and the
prevalence of BRCA2 mutations was 6 % [26]. The rela-
tively low frequency of BRCA1 mutations reported here
may be explained by a lower prevalence of mutations in
this particular region of Poland, noticed and reported
previously by Blecharz et al and Brozek et al [28, 33].
The frequency of BRCA2 mutations in this study (8.3 %)
is within the range of mutation frequencies reported
in previous studies of Polish families (2.6 to 11.4 %)
[24, 34–37].
The two most frequent mutations identified in the
present study were the BRCA1 founder mutations
c.5266dupC (identified in six patients) and c.181 T > G
(identified in four patients). These two founder muta-
tions accounted for 91 % of all BRCA1 mutation car-
riers, which in general is consistent with previous studies
in the Polish population (Table 4) [26, 33, 38, 39]. How-
ever, in our study BRCA1 founder mutations accounted
for only 48 % of all BRCA1 and BRCA2 mutation carriers,
whereas in previous studies BRCA1 founder mutations
accounted for 80 to 90 % of all BRCA1/2 carriers [26, 28,
32]. In most previous studies there was a preponderance
of BRCA1 mutations over BRCA2 mutations. In our
study, the frequency of BRCA1 and BRCA2 mutations is
similar, and BRCA2 mutations make a larger contribution
to all BRCA1/2 mutation carriers. The relatively low ratio
of BRCA1 to BRCA2 mutations reported here may be due
to the low prevalence of BRCA1 founder mutations
in this region (discussed above) or perhaps there has
not been enough BRCA2 mutation screening in Poland
because of the lack of founder mutations and more re-
search is warranted. Nevertheless, it is of particular
importance to identify recurrent mutations of BRCA2 in
this population.
Three of the seven different BRCA2 mutations identi-
fied in the current study were recurrent (i.e. found in
more than one patient). Two patients carried the likely
pathogenic BRCA2 mutation c.9371A > T. This substitu-
tion is located in an evolutionarily conserved region of
the BRCA2 gene and is predicted to adversely affect
ssDNA interaction and the structural integrity of the C-
terminal domain of the protein [40, 41]. This variant has
previously been reported in 11 unrelated patients from
Poland (Table 3) [25, 34, 36, 42]. Kluska et al recently
identified the variant in six patients and proposed its in-
clusion in the list of Polish founder mutations [25]. Two
patients carried the BRCA2 mutation c.9403delC. This
mutation has been previously reported in six unrelated
patients from Poland (Table 3), including three patients
from Southern Poland [34]. The mutation has also been
reported in patients from the Czech Republic and
Slovakia [43, 44]. This variant may be a local founder
mutation and should be included as a part of the screen-
ing test for the Polish population. Two patients carried
the BRCA2 mutation c.1310_1313delAAGA. This muta-
tion has not been previously reported in other studies
from Poland. However, it has been frequently reported
in Denmark and less frequently in France, Spain and
North Africa [45–47]. The prevalence of this mutation
in Southern Poland should be examined further. Includ-
ing the two recurrent BRCA2 mutations that have been
previously identified in the Polish population (c.9371A > T
and c.9403delC) in the standard testing panel would in-
crease the sensitivity of the panel for all BRCA1/2 muta-
tion carriers from 48 to 67 %.
One patient carried the BRCA2 frame-shift variant
c.10095delCinsGAATTATATCT. This variant truncates
the BRCA2 protein at the very end of the C-terminus
and according to the BIC database is most likely benign.
We classified this variant as non-pathogenic, however
there is one previous report which suggests a potential
association of the variant with familial aggregation of
breast and/or ovarian cancer [48]. Furthermore, in our
family, the variant was identified in two first-degree rela-
tives with breast cancer, including one patient who was
diagnosed before age 50. This variant has now been
identified in four unrelated Polish patients (Table 3).
We identified the PALB2 mutation c.509_510delGA in
two unrelated patients (1.7 %), both of whom were diag-
nosed with breast cancer before age 50 and had one
affected relative. This mutation was recently identified in
70 (0.6 %) of 12,529 unselected breast cancer patients
from Poland, and is considered to be a recurrent muta-
tion in the Polish population [49, 50]. In a study of 144
Polish breast cancer families, the mutation was identified
in 1.4 % and accounted for 50 % of all PALB2 mutation
carriers [23]. The full spectrum of PALB2 mutations in
the population of southern Poland is not known. The
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Table 4 Basic panel (“standard panel”) of the five most common mutations identified in BRCA1 and their relative frequency in the Polish population
Mutation Looij (2000)
[52]
Grzybowska
(2000) [34]
Grzybowska
(2002) [53]
Perkowska
(2003) [39]
Górski
(2004) [32]
Górski
(2006) [38]
Brożek
(2008) [35]
Ratajska
(2008) [26]
Blecharz
(2009) [28]
Rzepecka
(2012) [54]
Gaj
(2012) [55]
Szwiec
(2015) [22]
Ratajska
(2015) [27]
Current
study
c.5266dupC 20 % 92 % 73 % 55 % 59 % 55 % 46 % 57 % 57 % 62 % 66 % 52 % 62 % 60 %
c.181 T > G 60 % 8 % 13 % 27 % 27 % 21 % 8 % 24 % 29 % 16 % 22 % 25 % 15 % 40 %
c.4035delA 0 % 0 % 0 % 0 % 10 % 12 % 8 % 0 % 8 % 5 % 1 % 4 % 0 % 0 %
c.3700_3704delGTAAA 20 % 0 % 0 % 9 % 3 % 6 % 31 % 11 %
6 %
14 % 6 % 12 % 23 % 0 %
c.68_69delAG 0 % 0 % 13 % 9 % 1 % 6 % 8 % 8 % 3 % 5 % 7 % 0 % 0 %
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prevalence of this mutation in unselected breast cancer
patients in the neighboring countries is as follows:
Germans 0.3 %, Russians 0.2 % and Belarusians 0.3 % [51].
PALB2 c.509_510delGA is one of two recurrent PALB2
mutations that have been recently described in the Polish
population. The other mutation, c.172_175delTTGT, has
been identified in 0.3 % of unselected breast cancer pa-
tients and 0.7 % of familial breast cancer patients from
Poland [23, 49]. Among families with three or more breast
cancers, the detection rate of 509_510delGA and 172_
175delTTGT PALB2 mutations increases to 4.6 %. The
risk of developing breast cancer is more than four times
higher in PALB2 mutation carriers compared to non-
carriers. Among those who develop breast cancer, the risk
of dying at ten years is two times higher for PALB2
mutation carriers compared to non-carriers (HR = 2.3;
p < 0.0001).
In summary, we have identified five recurrent muta-
tions in women with familial and/or early-onset breast
and/or ovarian cancer from Southern Poland; BRCA1
c.5266dupC in six patients (prevalence: 5 %), BRCA1
c.181 T > G in four patients (prevalence: 3.3 %), BRCA2
likely pathogenic c.9371A > T in two patients, (1.7 %),
BRCA2 c.9403delC in two patients (1.7 %) and PALB2
c.509_510delGA in two patients (1.7 %). Including the
three additional recurrent mutations to the standard
testing panel of BRCA1 founder mutations would in-
crease the mutation detection rate from 8.3 to 13.4 %.
Conclusions
Based on the results presented above and data from pre-
vious studies we conclude that (i) the “standard panel”
of five BRCA1 founder mutations, described published
previously by different Polish groups is sufficiently sensi-
tive to identify BRCA1 mutation carriers in a screening
test and (ii) the recurrent BRCA2 mutations N3124I and
9631delC as well as the recurrent PALB2 mutation
c.509_510delGA could be included in the testing panel
for the Southern Polish population. The proposed en-
largement of the mutation set used for routine screening
for familial and/or early-onset breast and/or ovarian can-
cer might turn-out to be beneficial for the patients.
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